Newsroom
Stay up to date on the latest Legend news and information from Legend Biotech.
Stay up to date on the latest Legend news and information from Legend Biotech.
SOMERSET, N.J.—(BUSINESS WIRE)— November 16, 2020—Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech” or the “Company”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today reported financial results for the quarter ended September 30, 2020. “Legend Biotech continues to execute on our corporate strategy, […]
Nov 16, 2020
Ye (Sally) Wang Appointed Chairwoman of the Board Ying Huang Named CEO SOMERSET, N.J., November 9, 2020—Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that Ms. Ye (Sally) Wang was appointed, effective November 6, […]
Nov 09, 2020
SOMERSET, N.J., November 5, 2020—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that new and updated data from CARTITUDE-1 and LEGEND-2 studies, respectively, will be presented at the 62nd American Society of Hematology (ASH) […]
Nov 05, 2020
SOMERSET, N.J.—(BUSINESS WIRE)—September 28, 2020—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, will participate in the Jefferies Virtual Cell Therapy Summit on Tuesday, October 6th. Ying Huang, interim-Chief Executive Officer and Chief Financial Officer, will represent […]
Sep 28, 2020
September 21, 2020 – SOMERSET, N.J. – Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global, clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that its Board of Directors has appointed Dr. Ying Huang as interim Chief Executive Officer, effective immediately. Dr. Huang […]
Sep 21, 2020
Thank you for your interest in learning more about Legend Biotech.
media@legendbiotech.com
You are going to a website that Legend Biotech does not operate and to which Legend Biotech's privacy policy does not apply. Legend Biotech is not responsible for the content, format, maintenance or policies of the website you are about to visit and does not endorse or monitor any content on such website.